期刊文献+

安体舒通对大鼠慢性环孢素A肾毒性的保护作用

Protective effects of Spironolactone on chronic cyclosporine A nephrotoxicity in rat models
下载PDF
导出
摘要 目的:观察醛固酮拮抗剂——安体舒通对慢性环孢素A(CsA)肾毒性发生及发展的影响。方法:健康雄性SD大鼠,低盐饮食1周后随机分为对照组(n=12)、模型组(CsA皮下注射,n=12)和治疗组(CsA皮下注射+安体舒通灌胃,n=12)。于实验35d时处死大鼠,检测大鼠肌酐清除率(Ccr)、血醛固酮水平,Masson染色观察肾脏病理,免疫组化检测肾组织转化生长因子-β1(TGF-β1)的表达。结果:与对照组相比,模型组大鼠体重明显下降(P<0.01),给予安体舒通后大鼠体重下降减慢(P<0.05);与对照组比较,模型组、治疗组大鼠Ccr均下降(P<0.05),但治疗组较模型组下降缓慢(P<0.05);与对照组比较,模型组、治疗组大鼠血醛固酮水平均明显升高(P<0.05),但治疗组与模型组相比,无显著性差异;与对照组相比,模型组大鼠肾脏出现明显间质纤维化(P<0.05),治疗组较模型组明显减轻(P<0.05);与对照组相比,模型组肾组织TGF-β1表达增强(P<0.05),治疗组较模型组明显减弱(P<0.05)。结论:醛固酮参与慢性CsA肾毒性的发生及发展,安体舒通可抑制慢性CsA肾毒性肾组织中TGF-β1的表达,进而抑制CsA诱导的肾间质纤维化。 objective:To investigate the effect of Spironolactone on chronic cyclosporine A nephrotoxicity in rat models.Methods:Normal male SD rats with low-salt diet were randomly divided into three groups,control group(n=12),model group(CsA subcutaneous daily injection,n=12)and treatment group(CsA subcutaneous injection and Spironolactone given by gastric gavage,n=12).At the 35th day of the experiment,creatinine clearance rate(Ccr)and serum aldosterone were determined.Masson staining and immunohistochemistry were performed to observe the morphological changes and TGF-β1 expression.Results:In comparison with control group,the rat body weight of model group was significantly decreased(P〈0.01),these were significantly ameliorated by Spironolactone(P〈0.05);the Ccr of model group and treatment group was decreased compared with the control group(P〈0.05),but that of treatment group decreased slowly than that of model group(P〈0.05).Blood aldosterone level of model group and treatment group was increased compared with that of control group(P〈0.05),but that of treatment group showed no significant difference compared with that of model group.The rat kidney of model group occurred obvious tubulointerstitial fibrosis compared with control group(P〈0.05),and that of treatment group was obviously released than that of model group(P〈0.05).The TGF-β1 of model group was higher(P〈0.05)and that of treatment group was lower than that of control group(P〈0.05).Conclusion:Aldosterone plays an important role in producing function and structural changes associated with chronic CsA nephrotoxicity.Spironolactone improves the tubulointerstitial fibrosis induced by CsA through inhibiting the expression of TGF-β1.
出处 《中国医药导报》 CAS 2009年第27期26-28,共3页 China Medical Herald
关键词 醛固酮 安体舒通 肾小管间质纤维化 转化生长因子-Β1 Aldosterone Spironolactone Tubulointerstitium fibrosis TGF-β1
  • 相关文献

参考文献12

  • 1Danovitch GM. Immunosuppressive medications for renal transplantation: a multiple choice question [J]. Kidney Int,2001,59(1):388-402.
  • 2Szabo A, Muller V. Cause of late renal transplant dysfunction [J]. Orv Hetil,2002,143(51):2811-2819.
  • 3Campistol JM, Sacks SH. Mechanisms of nephrotoxicity [J]. Transplantation,2000,69(Suppl 12):S5-10.
  • 4Olyaei A J, deMattos AM, Bennett WM. A practical guide to the management of hypertension in renal transplant recipients [J]. Drugs,1999,58(6): 1011-1027.
  • 5Burodmann EA, Andoh IF, Yu L, et al. Cyclosporine nephortoxicity [J]. Semin Nephrol,2003,23:465-476.
  • 6刘章锁,王沛,程根阳,李海建,刘淑真,李继昌,刘钟明.罗格列酮对实验性慢性环孢素肾病的作用[J].中华肾脏病杂志,2007,23(4):235-241. 被引量:14
  • 7Aros C, Renmzzi G. The renin-angiotensin system in progression, remission and regression of chronic nephropathies [J]. J Hypertens,2002,20:S45- S53.
  • 8Rocha R, Stier CT, Kifor I, et al. Aldosterone: a mediator of myocardial necrosis and renal arteriopathy [J]. Endocrinology 2000,141(10):3871-3878.
  • 9Hostetter TH, Rosenberg ME, Ibrahim HN, et al. Aldosterone in progressive renal disease [J]. Semin Nephrol,2001,21(6):573-579.
  • 10Kang DH, Kim YG, Andoh TH, et al. Post-cyclosporine-mediated hypertension and nephropathy: amelioration by vascular endothelial growth factor [J]. Am J Physiol Renal Physiol,2001,280(4):F727-736.

二级参考文献15

  • 1林沁,顾勇,马骥,林善锬.罗格列酮对肾间质损伤的防护作用及其机制[J].中华医学杂志,2005,85(23):1618-1624. 被引量:9
  • 2Kyriakides G, Miller J. Use of cyclosporine in renal transplantation. Transplantation Proc, 2004, 36: S167- S172.
  • 3Ma LJ, Marcantoni C, Linton MF, et al. Peroxisome proliferator- activated receptor-gamma agonist troglitazone protects against nondiabetic glomerulosclerosis in rats. Kidney Int, 2001, 59:1899-1910.
  • 4Jiang C, Ting AT, Seed B. PPARτ agonists inhibit production of monocyte inflammatory cytokines. Nature,1998, 391:82-86.
  • 5Routh RE, Johnson JH, McCarthy KJ. Troglitazone suppresses the secretion of type Ⅰ collagen by mesangial cells in vitro.Kidney Int, 2002, 61:1365-1376.
  • 6Maki U, Masanori W, Tetsuro A, et al. PPARτ ligands attenuate mesangial contractile dysfunction in high glucose.Kidney Int, 2004, 65:961-971.
  • 7Verpooten GA, Cools FJ, Van der Planken MG, et al.Elevated plasminogen activator inhibitor levels in cyclosporin-treated renal allograft recipients. Nephrol Dial Transplant, 1996, 11:347-351.
  • 8Duymelinck C, Deng JT, Dauwe SE, et al. Inhibition of the matrix metalloproteinase system in a rat model of chronic cyclosporine nephropathy. Kidney Int, 1998, 54:804-818.
  • 9Waiser J, Dell K, Bohler T, et al. Cyclosporine A upregulates the expression of TGF-β1 and its receptors type Ⅰ and type Ⅱ in rat mesangial cells. Nephrol Dial Transplant,2002, 17:1568-1577.
  • 10Wolf G, Thaiss F, Stahl RA. Cyclosporine stimulates expression of transforming growth factor-beta in renal cells.Possible mechanism of cyclosporines antiproliferative effects.Transplantation, 1995, 60:237-241.

共引文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部